{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:59:10Z","timestamp":1788580750489,"version":"build-2803163510"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s11255-021-02848-0","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T11:02:52Z","timestamp":1617361372000},"page":"309-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"54","author":[{"given":"Kullaya","family":"Takkavatakarn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thunyatorn","family":"Wuttiputhanun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeerath","family":"Phannajit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kearkiat","family":"Praditpornsilpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somchai","family":"Eiam-Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9813-9219","authenticated-orcid":false,"given":"Paweena","family":"Susantitaphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"issue":"3","key":"2848_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/toxins11030175","volume":"11","author":"C Rodelo-Haad","year":"2019","unstructured":"Rodelo-Haad C, Santamaria R, Munoz-Castaneda JR, Pendon-Ruiz de Mier MV, Martin-Malo A, Rodriguez M (2019) FGF23, biomarker or target? Toxins (Basel) 11(3):175","journal-title":"Toxins (Basel)"},{"issue":"7120","key":"2848_CR2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K et al (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444(7120):770\u2013774","journal-title":"Nature"},{"issue":"2","key":"2848_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41581-018-0087-2","volume":"15","author":"M Vervloet","year":"2019","unstructured":"Vervloet M (2019) Renal and extrarenal effects of fibroblast growth factor 23. Nat Rev Nephrol 15(2):109\u2013120","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"2848_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19(3):429\u2013435","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2848_CR5","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79(12):1370\u20131378","journal-title":"Kidney Int"},{"issue":"7","key":"2848_CR6","doi-asserted-by":"publisher","first-page":"e003486","DOI":"10.1161\/JAHA.116.003486","volume":"5","author":"R Haring","year":"2016","unstructured":"Haring R, Enserro D, Xanthakis V, Mitchell GF, Benjamin EJ, Hamburg NM et al (2016) Plasma fibroblast growth factor 23: clinical correlates and association with cardiovascular disease and mortality in the Framingham heart study. J Am Heart Assoc 5(7):e003486","journal-title":"J Am Heart Assoc"},{"key":"2848_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/ckj\/sfaa028","volume":"14","author":"A Bouma-de Krijger","year":"2020","unstructured":"Bouma-de Krijger A, de Roij van Zuijdewijn CLM, Nub\u00e9 MJ, Grooteman MPC, Vervloet MG (2020) Change in FGF23 concentration over time and its association with all-cause mortality in patients treated with haemodialysis or haemodiafiltration. Clin Kidney J 14:891\u2013897","journal-title":"Clin Kidney J"},{"issue":"2","key":"2848_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/MAJ.0b013e3181815498","volume":"337","author":"HJ Hsu","year":"2009","unstructured":"Hsu HJ, Wu MS (2009) Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 337(2):116\u2013122","journal-title":"Am J Med Sci"},{"issue":"1","key":"2848_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000339026","volume":"36","author":"A Unsal","year":"2012","unstructured":"Unsal A, Kose Budak S, Koc Y, Basturk T, Sakaci T, Ahbap E et al (2012) Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease. Kidney Blood Press Res 36(1):55\u201364","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"2848_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","volume":"205","author":"MA Mirza","year":"2009","unstructured":"Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205(2):385\u2013390","journal-title":"Atherosclerosis"},{"issue":"3","key":"2848_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.kint.2016.10.021","volume":"91","author":"J Munoz Mendoza","year":"2017","unstructured":"Munoz Mendoza J, Isakova T, Cai X, Bayes LY, Faul C, Scialla JJ et al (2017) Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int 91(3):711\u2013719","journal-title":"Kidney Int"},{"issue":"10","key":"2848_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1-34","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2848_CR13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S0197-2456(99)00026-4","volume":"20","author":"HD Clark","year":"1999","unstructured":"Clark HD, Wells GA, Huet C, McAlister FA, Salmi LR, Fergusson D et al (1999) Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 20(5):448\u2013452","journal-title":"Control Clin Trials"},{"issue":"9","key":"2848_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle\u2013Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"2848_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11(2):193\u2013206","journal-title":"Psychol Methods"},{"issue":"7109","key":"2848_CR16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"issue":"2","key":"2848_CR17","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/ndt\/gfq419","volume":"26","author":"T Isakova","year":"2011","unstructured":"Isakova T, Gutierrez OM, Smith K, Epstein M, Keating LK, Juppner H et al (2011) Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 26(2):584\u2013591","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2848_CR18","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2215\/CJN.09250912","volume":"8","author":"T Isakova","year":"2013","unstructured":"Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J et al (2013) Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 8(6):1009\u20131018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2848_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ndt\/gfs405","volume":"28","author":"M Sigrist","year":"2013","unstructured":"Sigrist M, Tang M, Beaulieu M, Espino-Hernandez G, Er L, Djurdjev O et al (2013) Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial. Nephrol Dial Transplant 28(1):161\u2013169","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2848_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/CJN.05420709","volume":"5","author":"RB Oliveira","year":"2010","unstructured":"Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L et al (2010) Early control of PTH and FGF23 in normophosphatemic ckd patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5(2):286\u2013291","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2848_CR21","doi-asserted-by":"publisher","first-page":"c74","DOI":"10.1159\/000319650","volume":"117","author":"AL Cancela","year":"2011","unstructured":"Cancela AL, Oliveira RB, Graciolli FG, dos Reis LM, Barreto F, Barreto DV et al (2011) Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract 117(1):c74\u2013c82","journal-title":"Nephron Clin Pract"},{"issue":"8","key":"2848_CR22","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1681\/ASN.2012030223","volume":"23","author":"GA Block","year":"2012","unstructured":"Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM et al (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23(8):1407\u20131415","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2848_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","volume":"59","author":"MI Yilmaz","year":"2012","unstructured":"Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T et al (2012) Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 59(2):177\u2013185","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2848_CR24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1681\/ASN.2012070719","volume":"24","author":"CD Chue","year":"2013","unstructured":"Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L et al (2013) Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 24(5):842\u2013852","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2848_CR25","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1093\/ndt\/gft203","volume":"28","author":"A Covic","year":"2013","unstructured":"Covic A, Passlick-Deetjen J, Kroczak M, Buschges-Seraphin B, Ghenu A, Ponce P et al (2013) A comparison of calcium acetate\/magnesium carbonate and sevelamer\u2013hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 28(9):2383\u20132392","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"2848_CR26","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/nep.12319","volume":"19","author":"HH Lin","year":"2014","unstructured":"Lin HH, Liou HH, Wu MS, Lin CY, Huang CC (2014) Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum K lotho levels in chronic haemodialysis patients. Nephrology (Carlton) 19(11):672\u2013678","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"2848_CR27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/1744-9987.12461","volume":"20","author":"T Akizawa","year":"2016","unstructured":"Akizawa T, Origasa H, Kameoka C, Tsukada J, Kuroishi K, Yamaguchi Y (2016) Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Ther Apher Dial 20(6):588\u2013597","journal-title":"Ther Apher Dial"},{"issue":"12","key":"2848_CR28","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.2215\/CJN.03030317","volume":"12","author":"S Liabeuf","year":"2017","unstructured":"Liabeuf S, Ryckelynck JP, El Esper N, Urena P, Combe C, Dussol B et al (2017) Randomized clinical trial of sevelamer carbonate on serum K lotho and fibroblast growth factor 23 in CKD. Clin J Am Soc Nephrol 12(12):1930\u20131940","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2848_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1053\/j.ajkd.2019.01.029","volume":"74","author":"B Ruggiero","year":"2019","unstructured":"Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R et al (2019) Effects of sevelamer carbonate in patients with CKD and proteinuria: the answer randomized trial. Am J Kidney Dis 74(3):338\u2013350","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2848_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5414\/CN107257","volume":"78","author":"T Toida","year":"2012","unstructured":"Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S et al (2012) Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clin Nephrol 78(3):216\u2013223","journal-title":"Clin Nephrol"},{"issue":"1","key":"2848_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1721727X1301100108","volume":"11","author":"JF Navarro-Gonz\u00e1lez","year":"2013","unstructured":"Navarro-Gonz\u00e1lez JF, Donate-Correa J, Muros M, Garc\u00eda-Garc\u00eda P, Getino MA, Garc\u00eda-P\u00e9rez J et al (2013) Lanthanum carbonate modulates inflammatory profile in hemodialysis patients: relationship with fibroblast growth factor-23. Eur J Inflamm 11(1):75\u201386","journal-title":"Eur J Inflamm"},{"issue":"2","key":"2848_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000353569","volume":"38","author":"ME Seifert","year":"2013","unstructured":"Seifert ME, de las Fuentes L, Rothstein M, Dietzen DJ, Bierhals AJ, Cheng SC et al (2013) Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol 38(2):158\u2013167","journal-title":"Am J Nephrol"},{"issue":"1","key":"2848_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5414\/CN107764","volume":"80","author":"S Soriano","year":"2013","unstructured":"Soriano S, Ojeda R, Rodriguez M, Almaden Y, Rodriguez M, Martin-Malo A et al (2013) The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol 80(1):17\u201322","journal-title":"Clin Nephrol"},{"key":"2848_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1471-2369-15-71","volume":"15","author":"P Urena-Torres","year":"2014","unstructured":"Urena-Torres P, Prie D, Keddad K, Preston P, Wilde P, Wan H et al (2014) Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the prefect study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC Nephrol 15:71","journal-title":"BMC Nephrol"},{"issue":"5","key":"2848_CR35","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s10157-016-1362-9","volume":"21","author":"YM Chang","year":"2017","unstructured":"Chang YM, Tsai SC, Shiao CC, Liou HH, Yang CL, Tung NY et al (2017) Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients. Clin Exp Nephrol 21(5):908\u2013916","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"2848_CR36","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1681\/ASN.2018101058","volume":"30","author":"JH Ix","year":"2019","unstructured":"Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK et al (2019) Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the combine trial. J Am Soc Nephrol 30(6):1096\u20131108","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2848_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2215\/CJN.05170513","volume":"9","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K et al (2014) Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9(3):543\u2013552","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2848_CR38","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","volume":"65","author":"GA Block","year":"2015","unstructured":"Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE et al (2015) A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3\u20135. Am J Kidney Dis 65(5):728\u2013736","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2848_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12882-016-0391-7","volume":"17","author":"MA Roberts","year":"2016","unstructured":"Roberts MA, Huang L, Lee D, MacGinley R, Troster SM, Kent AB et al (2016) Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial. BMC Nephrol 17(1):177","journal-title":"BMC Nephrol"},{"issue":"6","key":"2848_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1159\/000489964","volume":"47","author":"N Maruyama","year":"2018","unstructured":"Maruyama N, Otsuki T, Yoshida Y, Nagura C, Kitai M, Shibahara N et al (2018) Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin responsiveness in hemodialysis patients. Am J Nephrol 47(6):406\u2013414","journal-title":"Am J Nephrol"},{"issue":"3","key":"2848_CR41","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000490903","volume":"140","author":"T Otsuki","year":"2018","unstructured":"Otsuki T, Utsunomiya K, Moriuchi M, Horikoshi S, Okamura M, Suzuki H et al (2018) Effect of sucroferric oxyhydroxide on fibroblast growth factor 23 levels in hemodialysis patients. Nephron 140(3):161\u2013168","journal-title":"Nephron"},{"issue":"8","key":"2848_CR42","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1681\/ASN.2018101016","volume":"30","author":"GA Block","year":"2019","unstructured":"Block GA, Block MS, Smits G, Mehta R, Isakova T, Wolf M et al (2019) A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD. J Am Soc Nephrol 30(8):1495\u20131504","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2848_CR43","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/ndt\/gfy127","volume":"34","author":"M Ketteler","year":"2019","unstructured":"Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V et al (2019) Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant 34(7):1163\u20131170","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2848_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"132","author":"SM Moe","year":"2015","unstructured":"Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R et al (2015) Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 132(1):27\u201339","journal-title":"Circulation"},{"issue":"6","key":"2848_CR45","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2215\/CJN.03270314","volume":"10","author":"SM Sprague","year":"2015","unstructured":"Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M et al (2015) Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism. Clin J Am Soc Nephrol 10(6):1021\u20131030","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"2848_CR46","first-page":"1723","volume":"32","author":"M Fukagawa","year":"2017","unstructured":"Fukagawa M, Yokoyama K, Shigematsu T, Akiba T, Fujii A, Kuramoto T et al (2017) A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 32(10):1723\u20131730","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2848_CR47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/ckj\/sfz034","volume":"13","author":"M Wolf","year":"2020","unstructured":"Wolf M, Block GA, Chertow GM, Cooper K, Fouqueray B, Moe SM et al (2020) Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clin Kidney J 13(1):75\u201384","journal-title":"Clin Kidney J"},{"issue":"10","key":"2848_CR48","doi-asserted-by":"publisher","first-page":"e0204896","DOI":"10.1371\/journal.pone.0204896","volume":"13","author":"T Akizawa","year":"2018","unstructured":"Akizawa T, Shimazaki R, Fukagawa M (2018) Phase 2b study of evocalcet (khk7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: a randomized, double-blind, placebo-controlled, dose-finding study. PLoS ONE 13(10):e0204896","journal-title":"PLoS ONE"},{"issue":"4","key":"2848_CR49","doi-asserted-by":"publisher","first-page":"E652","DOI":"10.1210\/jc.2013-4050","volume":"99","author":"H Takahashi","year":"2014","unstructured":"Takahashi H, Komaba H, Takahashi Y, Sawada K, Tatsumi R, Kanai G et al (2014) Impact of parathyroidectomy on serum FGF23 and soluble K lotho in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Endocrinol Metab 99(4):E652\u2013E658","journal-title":"J Clin Endocrinol Metab"},{"key":"2848_CR50","first-page":"6453803","volume":"2016","author":"SC Liao","year":"2016","unstructured":"Liao SC, Moi SH, Chou FF, Yang CH, Chen JB (2016) Changes in serum concentrations of fibroblast growth factor 23 and soluble K lotho in hemodialysis patients after total parathyroidectomy. Biomed Res Int 2016:6453803","journal-title":"Biomed Res Int"},{"issue":"4","key":"2848_CR51","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3892\/etm.2014.1543","volume":"7","author":"LY Miao","year":"2014","unstructured":"Miao LY, Zhu B, He XZ, Liu JF, Jin LN, Li XR et al (2014) Effects of three blood purification methods on serum fibroblast growth factor-23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis. Exp Ther Med 7(4):947\u2013952","journal-title":"Exp Ther Med"},{"key":"2848_CR52","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.12659\/MSM.894894","volume":"21","author":"X Fu","year":"2015","unstructured":"Fu X, Cui QQ, Ning JP, Fu SS, Liao XH (2015) High-flux hemodialysis benefits hemodialysis patients by reducing serum FGF-23 levels and reducing vascular calcification. Med Sci Monit 21:3467\u20133473","journal-title":"Med Sci Monit"},{"issue":"5","key":"2848_CR53","doi-asserted-by":"publisher","first-page":"e0128079","DOI":"10.1371\/journal.pone.0128079","volume":"10","author":"A Schneider","year":"2015","unstructured":"Schneider A, Schneider MP, Krieter DH, Genser B, Scharnagl H, Stojakovic T et al (2015) Effect of high-flux dialysis on circulating FGF-23 levels in end-stage renal disease patients: results from a randomized trial. PLoS ONE 10(5):e0128079","journal-title":"PLoS ONE"},{"issue":"26","key":"2848_CR54","first-page":"2074","volume":"95","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Chen J, Sun Z, Chen C, Xue J, Liu X et al (2015) Effects of high-flux hemodialysis on FGF-23 and micro-inflammatory state in end-stage renal diseases patients. Zhonghua Yi Xue Za Zhi 95(26):2074\u20132078","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"4","key":"2848_CR55","first-page":"2007","volume":"35","author":"Z Zulong","year":"2019","unstructured":"Zulong Z, Rui Y, Bol L, Ye C (2019) Effect of high-flux hemodialysis on FGF23 level, calcium\u2013phosphate metabolism disorder, arteriosclerosis, and cardiac function in patients with end-stage renal disease. Acta Med Mediterr 35(4):2007\u20132011","journal-title":"Acta Med Mediterr"},{"issue":"5","key":"2848_CR56","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/ndt\/gfr596","volume":"27","author":"L Viaene","year":"2012","unstructured":"Viaene L, Bammens B, Meijers BK, Vanrenterghem Y, Vanderschueren D, Evenepoel P (2012) Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrol Dial Transplant 27(5):2017\u20132022","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2848_CR57","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.krcp.2014.01.001","volume":"33","author":"H Rhee","year":"2014","unstructured":"Rhee H, Yang JY, Jung WJ, Shin MJ, Yang BY, Song SH et al (2014) Significance of residual renal function for phosphate control in chronic hemodialysis patients. Kidney Res Clin Pract 33(1):58\u201364","journal-title":"Kidney Res Clin Pract"},{"issue":"12","key":"2848_CR58","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1210\/en.2005-0777","volume":"146","author":"F Perwad","year":"2005","unstructured":"Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA (2005) Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146(12):5358\u20135364","journal-title":"Endocrinology"},{"issue":"2","key":"2848_CR59","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2215\/CJN.04730510","volume":"6","author":"MG Vervloet","year":"2011","unstructured":"Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM (2011) Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 6(2):383\u2013389","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"2848_CR60","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1093\/ndt\/gfy005","volume":"33","author":"WC Tsai","year":"2018","unstructured":"Tsai WC, Wu HY, Peng YS, Hsu SP, Chiu YL, Chen HY et al (2018) Effects of lower versus higher phosphate diets on fibroblast growth factor-23 levels in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 33(11):1977\u20131983","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2848_CR61","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2215\/CJN.05040610","volume":"6","author":"SM Moe","year":"2011","unstructured":"Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL et al (2011) Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 6(2):257\u2013264","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2848_CR62","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2215\/CJN.07640711","volume":"7","author":"B Di Iorio","year":"2012","unstructured":"Di Iorio B, Di Micco L, Torraca S, Sirico ML, Russo L, Pota A et al (2012) Acute effects of very-low-protein diet on FGF23 levels: a randomized study. Clin J Am Soc Nephrol 7(4):581\u2013587","journal-title":"Clin J Am Soc Nephrol"},{"key":"2848_CR63","doi-asserted-by":"crossref","unstructured":"Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM (2020) Sarcopenia in chronic kidney disease: what have we learned so far? J Nephrol","DOI":"10.1007\/s40620-020-00840-y"},{"issue":"4","key":"2848_CR64","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2165\/11539120-000000000-00000","volume":"31","author":"YF Lin","year":"2011","unstructured":"Lin YF, Chien CT, Kan WC, Chen YM, Chu TS, Hung KY et al (2011) Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study. Clin Drug Investig 31(4):257\u2013267","journal-title":"Clin Drug Investig"},{"issue":"3","key":"2848_CR65","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10157-017-1504-8","volume":"22","author":"E Riccio","year":"2018","unstructured":"Riccio E, Sabbatini M, Bruzzese D, Grumetto L, Marchetiello C, Amicone M et al (2018) Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial. Clin Exp Nephrol 22(3):529\u2013538","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"2848_CR66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ki.2015.290","volume":"89","author":"V David","year":"2016","unstructured":"David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V et al (2016) Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89(1):135\u2013146","journal-title":"Kidney Int"},{"issue":"10","key":"2848_CR67","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1681\/ASN.2015020117","volume":"26","author":"T Isakova","year":"2015","unstructured":"Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ et al (2015) Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol 26(10):2328\u20132339","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2848_CR68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jare.2017.02.003","volume":"8","author":"UAA Sharaf El Din","year":"2017","unstructured":"Sharaf El Din UAA, Salem MM, Abdulazim DO (2017) Is fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review. J Adv Res 8(3):271\u2013278","journal-title":"J Adv Res"},{"issue":"15","key":"2848_CR69","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0755-4982(05)84125-9","volume":"34","author":"P Urena","year":"2005","unstructured":"Urena P, Legoupil N, de Vernejoul MC (2005) Calcimimetics, mechanisms of action and therapeutic applications. Press Med 34(15):1095\u20131100","journal-title":"Press Med"},{"issue":"3","key":"2848_CR70","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/j.1476-5381.2011.01317.x","volume":"164","author":"S Smajilovic","year":"2011","unstructured":"Smajilovic S, Yano S, Jabbari R, Tfelt-Hansen J (2011) The calcium-sensing receptor and calcimimetics in blood pressure modulation. Br J Pharmacol 164(3):884\u2013893","journal-title":"Br J Pharmacol"},{"issue":"3","key":"2848_CR71","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000487546","volume":"139","author":"P Greeviroj","year":"2018","unstructured":"Greeviroj P, Kitrungphaiboon T, Katavetin P, Praditpornsilpa K, Eiam-Ong S, Jaber BL et al (2018) Cinacalcet for treatment of chronic kidney disease-mineral and bone disorder: a meta-analysis of randomized controlled trials. Nephron 139(3):197\u2013210","journal-title":"Nephron"},{"issue":"11","key":"2848_CR72","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.2215\/CJN.04290511","volume":"6","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Barchi-Chung A, Vargas G, Sowden N, Houston J et al (2011) Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 6(11):2688\u20132695","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02848-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-021-02848-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02848-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T04:40:53Z","timestamp":1650256853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-021-02848-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2848"],"URL":"https:\/\/doi.org\/10.1007\/s11255-021-02848-0","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,2]]},"assertion":[{"value":"17 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, ethical approval is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study did not directly involve with human participants or animal subjects.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights statement"}}]}}